Opinion

Video

Role of ADCs in HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos Castillero, MD, FACP, FASCO,Martin Dietrich, MD, PhD

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Related Content
US FDA
May 15th 2025

FDA Approves Retifanlimab for Advanced Anal Cancer

Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, the University of California San Diego Health; Rachel N. Grisham, MD, associate attending physician, Memorial Sloan Kettering Cancer Center; Benjamin Herzberg, MD, assistant professor, medicine, Columbia University Medical Center, oncologist, Herbert Irving Comprehensive Cancer Center; Kelly McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA Health’s David Geffen School of Medicine; Gregory Roloff, MD, hematologist/oncologist, the University of Chicago Medicine
March 31st 2025

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

Advanced NSCLC | Image Credit: © catalin – stock.adobe.com
May 15th 2025

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

Ibrahim T. Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
March 20th 2025

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

Joshua K. Sabari, MD
May 15th 2025

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

FDA
May 14th 2025

FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression